From August 28, the State Institute of Drugs and Good Practices is authorized to inspect Russian pharmaceutical manufacturers for compliance with all GxP standards. This was announced by Dmitry Rozhdestvensky, the Head of Division of Medicines and Medical Products’ Circulation Coordination at the Technical Regulation and Accreditation Department of Eurasian Economic Commission (EEC).
There will be no special inspectorate to conduct inspections for compliance with GСP in the pharmaceutical market of Eurasian Economic Union (EAEU).
“From August 28, the Russian GMP inspectorate is authorized to conduct inspections for compliance with GMP of the Union. On September 1, the inspectorates in the Republic of Belarus and Armenia also started to receive applications to inspect for compliance with GMP of the Union,” said Dmitry Rozhdestvensky. “Our inspectorates are acquiring the same function as the inspectorates all over the world. There is a pharmaceutical inspectorate, which inspects for compliance with all good practices. Therefore, our national inspectorates, that previously operated only as GMP inspectorates, are acquiring the functions for inspecting all good practices. This may involve several organizations, one of which will be responsible for collaborating with inspectorates of other countries.”